Answers are grounded in this paper and cite their sources.
Background: Repeated COVID-19 vaccination effects on the immunogenicity, breadth, and durability of antibody responses across antigenically distinct SARS-CoV-2 variants remain incompletely understood. Method: Participants receiving >= five COVID-19 vaccine doses 2020-2025 were selected from a prospective cohort in Michigan. Serum IgG, IgM, and ACE2 percent inhibition were measured using multiplex assays. Baseline-adjusted immunogenicity, cross-reactivity, and formulation-specific antibody durability were evaluated using regression models. Result: Twenty-one participants were included (median: seven vaccine doses). For every two-fold increase in pre-vaccination IgG concentration, post-vaccination fold-rise was 34% (95% CI: 16%-48%), 43% (95% CI: 15%-62%), and 55% (95% CI: 21%-75%) lower following monovalent, bivalent, and 2023-24 vaccination, while baseline-adjusted immunogenicity showed no significant trends across successive vaccines. Antibody landscapes demonstrated broad cross-reactivity against ancestral and Omicron variants, with similar strain-specific IgG changes across ancestral, vaccine-matched, and antigenically distant strains, but greater heterogeneity in ACE2 inhibition. Formulation-specific waning models showed significant IgG declines following monovalent and bivalent vaccination (beta = -1.03, 95% CI: -1.51 to -0.55; P<0.001 and -1.00 , 95% CI: -1.71 to -0.30; P=0.007, respectively) and ACE2 inhibition declines following monovalent vaccination, while other formulations showed less consistent changes. Despite waning, antibody levels generally remained relatively high across variants up to 300 days post-vaccination, with formulation-specific differences in durability. Conclusion: Repeated COVID-19 vaccination maintained baseline-adjusted immunogenicity and broad cross-reactive antibody responses, with formulation-specific differences in durability. Higher baseline immunity was associated with smaller post-vaccination increases, suggesting repeated boosting continues to reinforce humoral immunity despite increasingly complex immune histories.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: